Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | CHIEF OPERATING OFFICER | May 16, 2024 | May 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date May 16, 2024 · Filed May 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2034-05-16 | Direct | 410,246 |
Reported balance
After 2024-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-16 · Grant · Acquired 50,000 · Balance 410,246 F1: On May 16, 2024, Adrian Haigh was granted incentive stock options to purchase 50,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan. F2: 2. One-third of the shares subject to this option may be exercised as of May 16, 2025 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this option may be exercised as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this option shall be vested. |
| Restricted Shste UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2034-05-16 | Direct | 435,246 |
Reported balance
After 2024-05-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-16 · Grant · Acquired 25,000 · Balance 435,246 F3: On May 16, 2024, Adrina Haigh was awarded restricted share units to acquire 25,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan F4: One-third of the shares subject to this award shall be released from restriction as of May 16, 2025 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction.. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 16, 2024, Adrian Haigh was granted incentive stock options to purchase 50,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan.
F2: 2. One-third of the shares subject to this option may be exercised as of May 16, 2025 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this option may be exercised as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this option shall be vested.
F3: On May 16, 2024, Adrina Haigh was awarded restricted share units to acquire 25,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan
F4: One-third of the shares subject to this award shall be released from restriction as of May 16, 2025 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction..
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2024 Filed May 21, 2024 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Shste Unit · Derivative | 25,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-013983 · form4-05212024_050508.xml · derivative · entry 2 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,246 Underlying: Common Shares · 25,000 shares Expires 2034-05-16 F3 · security: On May 16, 2024, Adrina Haigh was awarded restricted share units to acquire 25,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan F4 · derivative.exercise_date: One-third of the shares subject to this award shall be released from restriction as of May 16, 2025 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction.. Read SEC document |
| May 16, 2024 Filed May 21, 2024 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001415889-24-013983 · form4-05212024_050508.xml · derivative · entry 1 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,246 Underlying: Common Shares · 50,000 shares Expires 2034-05-16 F1 · security: On May 16, 2024, Adrian Haigh was granted incentive stock options to purchase 50,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: 2. One-third of the shares subject to this option may be exercised as of May 16, 2025 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this option may be exercised as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| April 22, 2024 Filed Apr 22, 2024 23:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionOption · Derivative | 22,223 | $2.31 Strike: $2.31 | $51,335.13 |
DisclosureSEC source: 0001415889-24-011336 · form4-04222024_110404.xml · derivative · entry 6 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 360,246 Underlying: Common Shares · 22,223 shares Expires 2024-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Represents option exercise pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 22, 2024 Filed Apr 22, 2024 23:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,223 | $9.32 | $207,029.47 |
DisclosureSEC source: 0001415889-24-011336 · form4-04222024_110404.xml · nonDerivative · entry 4 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F4 · security: Shares disposed pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 22, 2024 Filed Apr 22, 2024 23:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 22,223 | $2.31 | $51,335.13 |
DisclosureSEC source: 0001415889-24-011336 · form4-04222024_110404.xml · nonDerivative · entry 3 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 23:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionOption · Derivative | 22,222 | $2.31 Strike: $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011336 · form4-04222024_110404.xml · derivative · entry 5 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,469 Underlying: Common Shares · 22,222 shares Expires 2024-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents option exercise pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 23:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,222 | $9.34 | $207,442.37 |
DisclosureSEC source: 0001415889-24-011336 · form4-04222024_110404.xml · nonDerivative · entry 2 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · security: Shares disposed pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 23:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 22,222 | $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011336 · form4-04222024_110404.xml · nonDerivative · entry 1 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 18, 2024 Filed Apr 19, 2024 01:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 22,222 | $2.31 Strike: $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011190 · form4-04192024_010425.xml · derivative · entry 6 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426,913 Underlying: Options · 22,222 shares Expires 2024-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Option exercise made pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 18, 2024 Filed Apr 19, 2024 01:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,222 | $9.62 | $213,775.64 |
DisclosureSEC source: 0001415889-24-011190 · form4-04192024_010425.xml · nonDerivative · entry 4 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F4 · security: Shares disposed pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 18, 2024 Filed Apr 19, 2024 01:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,222 | $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011190 · form4-04192024_010425.xml · nonDerivative · entry 2 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,444 F2 · security: Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 18, 2024 Filed Apr 26, 2024 20:15 UTC Amendment | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 22,222 | $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011591 · form4a-04262024_040401.xml · nonDerivative · entry 2 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: On April 18, 2024, the reporting person filed a Form 4 that mistakenly indicated a transaction code of "S" in Column 3 of Table I concerning the reporting person's acquisition of 22,222 common shares on April 17, 2024, and an additional 22,222 common shares on April 18, 2024, each pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. The correct transaction code for the reporting person's acquisition of these shares is "M". Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 01:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 22,222 | $2.31 Strike: $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011190 · form4-04192024_010425.xml · derivative · entry 5 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 449,135 Underlying: Options · 22,222 shares Expires 2024-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Option exercise made pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 01:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,222 | $9.91 | $220,220.02 |
DisclosureSEC source: 0001415889-24-011190 · form4-04192024_010425.xml · nonDerivative · entry 3 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,222 F3 · security: Shares disposed pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 01:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,222 | $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011190 · form4-04192024_010425.xml · nonDerivative · entry 1 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,222 F1 · security: Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 17, 2024 Filed Apr 26, 2024 20:15 UTC Amendment | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 22,222 | $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011591 · form4a-04262024_040401.xml · nonDerivative · entry 1 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On April 18, 2024, the reporting person filed a Form 4 that mistakenly indicated a transaction code of "S" in Column 3 of Table I concerning the reporting person's acquisition of 22,222 common shares on April 17, 2024, and an additional 22,222 common shares on April 18, 2024, each pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. The correct transaction code for the reporting person's acquisition of these shares is "M". Read SEC document |
| April 16, 2024 Filed Apr 16, 2024 22:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 22,222 | $2.31 Strike: $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-010901 · form4-04162024_100446.xml · derivative · entry 6 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 449,135 Underlying: Options · 22,222 shares Expires 2024-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Option exercise made pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 16, 2024 Filed Apr 16, 2024 22:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,222 | $10.28 | $228,388.83 |
DisclosureSEC source: 0001415889-24-010901 · form4-04162024_100446.xml · nonDerivative · entry 4 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F4 · security: Shares acquired pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 16, 2024 Filed Apr 16, 2024 22:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,222 | $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-010901 · form4-04162024_100446.xml · nonDerivative · entry 2 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,444 F2 · security: Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 16, 2024 Filed Apr 26, 2024 20:10 UTC Amendment | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 22,222 | $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011584 · form4a-04262024_040402.xml · nonDerivative · entry 2 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: On April 16, 2024, the reporting person filed a Form 4 that mistakenly indicated a transaction code of "S" in Column 3 of Table I concerning the reporting person's acquisition of 22,222 common shares on April 15, 2024, and an additional 22,222 common shares on April 16, 2024, each pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. The correct transaction code for the reporting person's acquisition of these shares is "M". Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 22:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 22,222 | $2.31 Strike: $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-010901 · form4-04162024_100446.xml · derivative · entry 5 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,357 Underlying: Options · 22,222 shares Expires 2024-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Option exercise made pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 22:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,222 | $10.30 | $228,793.27 |
DisclosureSEC source: 0001415889-24-010901 · form4-04162024_100446.xml · nonDerivative · entry 3 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,222 F3 · security: Shares disposed pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 22:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 22,222 | $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-010901 · form4-04162024_100446.xml · nonDerivative · entry 1 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,222 F1 · security: Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. Read SEC document |
| April 15, 2024 Filed Apr 26, 2024 20:10 UTC Amendment | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 22,222 | $2.31 | $51,332.82 |
DisclosureSEC source: 0001415889-24-011584 · form4a-04262024_040402.xml · nonDerivative · entry 1 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On April 16, 2024, the reporting person filed a Form 4 that mistakenly indicated a transaction code of "S" in Column 3 of Table I concerning the reporting person's acquisition of 22,222 common shares on April 15, 2024, and an additional 22,222 common shares on April 16, 2024, each pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. The correct transaction code for the reporting person's acquisition of these shares is "M". Read SEC document |
| August 07, 2023 Filed Aug 7, 2023 20:01 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001415889-23-011895 · form4-08072023_080855.xml · derivative · entry 1 Haigh Adrian · CIK 0001717425 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,579 Underlying: Common Shares · 200,000 shares Expires 2033-08-07 F1 · date: On August 7, 2023, Adrian Haigh was granted a stock option to purchase 200,000 shares of the issuer's common shares pursuant to the issuers 2020 Euity Incentive Plan. F2 · derivative.exercise_date: One-third of grant will vest upon the first anniversary date of the grant. On the last day of each successive month, one-twenty fourth of the grant shall vest such that vesting is complete as of third anniversary of grant date. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 14:22 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001415889-23-009691 · form4-06132023_020615.xml · derivative · entry 1 Haigh Adrian · CIK 0001717425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293.579 Underlying: Common Shares · 20,000 shares Expires 2033-06-12 F1 · security: On June 12, 2023, Adrian Haigh was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested of date of grant. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 13:23 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001104659-22-071688 · tm2218610-3_4seq1.xml · derivative · entry 1 Haigh Adrian · CIK 0001717425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2032-06-14 F1 · security: On June 14, 2022, Adrian Haigh was granted a non-qualified stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 19:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001104659-21-087515 · tm2121155-3_4seq1.xml · derivative · entry 1 Haigh Adrian · CIK 0001717425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2031-06-29 F1 · security: On June 29, 2021, Adrian Haigh was granted a non-qualified stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 19:16 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001104659-20-095446 · tm2027709d3_4.xml · derivative · entry 1 Haigh Adrian · CIK 0001717425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2030-08-13 F1 · security: On August 13, 2020, Adrian Haigh was granted a non-qualified stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 00:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001144204-19-031565 · tv523894_4.xml · derivative · entry 1 Haigh Adrian · CIK 0001717425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2029-06-18 F1 · security: On June 18, 2019, Adrian Haigh was granted an incentive stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 14:43 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.93 | $0.00 |
DisclosureSEC source: 0001144204-18-033679 · tv496272_4.xml · derivative · entry 1 Haigh Adrian · CIK 0001717425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2025-06-08 F1 · security: On June 8, 2018, Adrian Haigh was granted an incentive stock option to purchase 20,000 common shares of the Issuer pursuant to the Issuer's Amended and Restated Stock Option Plan. The option is 100% vested on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.